| Name | Title | Contact Details |
|---|---|---|
Marcin Cieslik |
Director of Technology | Commercial & Medical IT | Biotech | Pharma | AI & Digital Innovation | Commercial Operations | Commercialization | New Product Launch | Global Expansion | Marketing | Veeva & Salesforce Certified | Profile |
Team Mental Health Services is dedicated to enhancing the well-being of individuals by providing an array of comprehensive behavioral and physical services in an environment that promotes quality of life, continuous improvement and social awareness. ...
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.
Founded in 2019, Engrail is supported by a long-term capital commitment from Nan Fung Life Sciences (NFLS).
TransparentRx is a fiduciary and transparent PBM company that specializes in providing effective solutions for self-funded employer groups, health plans, TPAs, business coalitions and government entities.
Option Care is a leading provider of home and alternate treatment site infusion services. With a staff of more than 1,700 clinical experts – including specially trained infusion nurses, infusion pharmacists and registered dietitians – Option Care treats patients with a wide range of acute and chronic conditions. Comprehensive therapy management programs are offered for patients with nutrition disorders, bleeding disorders and heart failure, as well as those needing immunoglobulin (IG) therapy and anti-infective therapy. Option Care is able to provide services to 92% of the nation`s population through more than 90 infusion pharmacies and 100 alternate treatment sites across the country.